Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension (CONFORM-OH): results from an internal pilot randomised controlled trial.

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Helen Mossop, Sarah Al-Ashmori, Tumi Sotire, Emma Clark, Gillian Watson, Miles D Witham, Luke Vale, Naomi McGregor, Julia Phillipson, James M S Wason, Alison J Yarnall, Steve Parry, Helen Hancock, Rose Anne Kenny, James Frith
{"title":"Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension (CONFORM-OH): results from an internal pilot randomised controlled trial.","authors":"Helen Mossop, Sarah Al-Ashmori, Tumi Sotire, Emma Clark, Gillian Watson, Miles D Witham, Luke Vale, Naomi McGregor, Julia Phillipson, James M S Wason, Alison J Yarnall, Steve Parry, Helen Hancock, Rose Anne Kenny, James Frith","doi":"10.1186/s40814-025-01704-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Orthostatic hypotension (OH) is a common debilitating condition characterised by a significant drop in blood pressure (BP) on standing upright. Adults with OH are typically offered non-pharmacologic therapies, either alone or in combination with medication. The two most used agents are fludrocortisone and midodrine. There is a lack of good quality evidence for any of these treatments, all of which are in widespread clinical use. The aim of this internal pilot trial was to evaluate recruitment, attrition, treatment crossover and quality of outcomes.</p><p><strong>Methods: </strong>The trial was designed as a pragmatic, open-label, randomised, prospective, multicentre, superior and multi-arm internal pilot. Recruitment was for 10 months, during which we aimed to open 14 sites and recruit a target of 64 adults with OH to evaluate feasibility of recruitment. Attrition, crossover and data collection were also assessed. Participants were randomised to one of three treatments: nondrug therapies (control), fludrocortisone plus nondrug therapies or midodrine plus nondrug therapies. Outcomes measured included symptoms, quality of life, activities of daily living, postural BP, use of health and care services, falls and safety. Participants received treatment and were followed up for 12 months. Pre-planned criteria to progress from internal pilot were defined for recruitment, retention, crossover and outcome completion.</p><p><strong>Results: </strong>Between the 3rd December 2021 and 31st August 2022, 13 participants were randomised from 4 of 9 recruiting centres. Redeployment of clinical and research staff, due to COVID-19, limited the number of available sites. Participants already receiving fludrocortisone or midodrine accounted for 120 of 233 eligible participants being excluded. Due to the low sample size, the rates of attrition and crossover are of limited value. Apart from the falls diaries, completion rates of the outcome measures were high (> 80%). Due to low recruitment rates, the pilot did not progress to the planned multi-arm multistage trial.</p><p><strong>Conclusions: </strong>In its current design, this trial was not feasible. The main barriers to success were participants already receiving treatment and redeployment of clinical and academic staff during and after the COVID-19 pandemic.</p><p><strong>Trial registration: </strong>ISRCTN 87213295, 23 July 2021, https://www.isrctn.com/ISRCTN87213295.</p>","PeriodicalId":20176,"journal":{"name":"Pilot and Feasibility Studies","volume":"11 1","pages":"118"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465824/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pilot and Feasibility Studies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40814-025-01704-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Orthostatic hypotension (OH) is a common debilitating condition characterised by a significant drop in blood pressure (BP) on standing upright. Adults with OH are typically offered non-pharmacologic therapies, either alone or in combination with medication. The two most used agents are fludrocortisone and midodrine. There is a lack of good quality evidence for any of these treatments, all of which are in widespread clinical use. The aim of this internal pilot trial was to evaluate recruitment, attrition, treatment crossover and quality of outcomes.

Methods: The trial was designed as a pragmatic, open-label, randomised, prospective, multicentre, superior and multi-arm internal pilot. Recruitment was for 10 months, during which we aimed to open 14 sites and recruit a target of 64 adults with OH to evaluate feasibility of recruitment. Attrition, crossover and data collection were also assessed. Participants were randomised to one of three treatments: nondrug therapies (control), fludrocortisone plus nondrug therapies or midodrine plus nondrug therapies. Outcomes measured included symptoms, quality of life, activities of daily living, postural BP, use of health and care services, falls and safety. Participants received treatment and were followed up for 12 months. Pre-planned criteria to progress from internal pilot were defined for recruitment, retention, crossover and outcome completion.

Results: Between the 3rd December 2021 and 31st August 2022, 13 participants were randomised from 4 of 9 recruiting centres. Redeployment of clinical and research staff, due to COVID-19, limited the number of available sites. Participants already receiving fludrocortisone or midodrine accounted for 120 of 233 eligible participants being excluded. Due to the low sample size, the rates of attrition and crossover are of limited value. Apart from the falls diaries, completion rates of the outcome measures were high (> 80%). Due to low recruitment rates, the pilot did not progress to the planned multi-arm multistage trial.

Conclusions: In its current design, this trial was not feasible. The main barriers to success were participants already receiving treatment and redeployment of clinical and academic staff during and after the COVID-19 pandemic.

Trial registration: ISRCTN 87213295, 23 July 2021, https://www.isrctn.com/ISRCTN87213295.

对照,氟可的松或米多宁治疗体位性低血压(conoh - oh):一项内部随机对照试验的结果。
背景:直立性低血压(OH)是一种常见的衰弱性疾病,其特征是直立站立时血压(BP)显著下降。成人氢氧化钠通常提供非药物治疗,无论是单独或联合药物。两种最常用的药物是氟化可的松和米多宁。这些治疗方法都在临床广泛使用,但缺乏高质量的证据。本内部试点试验的目的是评估招募、减员、治疗交叉和结果质量。方法:该试验设计为务实、开放标签、随机、前瞻性、多中心、优越和多臂内部试验。招募为期10个月,在此期间,我们计划开设14个站点,招募64名成年OH患者,以评估招募的可行性。还对减员、交叉和数据收集进行了评估。参与者被随机分配到三种治疗中的一种:非药物治疗(对照),氟可的松加非药物治疗或米多宁加非药物治疗。测量的结果包括症状、生活质量、日常生活活动、体位血压、健康和护理服务的使用、跌倒和安全。参与者接受治疗并随访12个月。制定了从内部试点发展的预先计划标准,包括招聘、保留、交叉和成果完成。结果:在2021年12月3日至2022年8月31日期间,从9个招募中心中的4个随机抽取了13名参与者。由于COVID-19,重新部署临床和研究人员限制了可用站点的数量。已接受氟可的松或米多宁治疗的受试者占233名被排除的合格受试者中的120名。由于样本量小,损耗率和交叉率的价值有限。除了跌倒日记外,结果测量的完成率也很高(约80%)。由于招募率低,试验没有进展到计划的多臂多阶段试验。结论:在目前的设计中,该试验是不可行的。成功的主要障碍是在COVID-19大流行期间和之后已经接受治疗的参与者以及临床和学术人员的重新部署。试验注册:ISRCTN87213295, 2021年7月23日,https://www.isrctn.com/ISRCTN87213295。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pilot and Feasibility Studies
Pilot and Feasibility Studies Medicine-Medicine (miscellaneous)
CiteScore
2.70
自引率
5.90%
发文量
241
审稿时长
9 weeks
期刊介绍: Pilot and Feasibility Studies encompasses all aspects of the design, conduct and reporting of pilot and feasibility studies in biomedicine. The journal publishes research articles that are intended to directly influence future clinical trials or large scale observational studies, as well as protocols, commentaries and methodology articles. The journal also ensures that the results of all well-conducted, peer-reviewed, pilot and feasibility studies are published, regardless of outcome or significance of findings. Pilot and feasibility studies are increasingly conducted prior to a full randomized controlled trial. However, these studies often lack clear objectives, many remain unpublished, and there is confusion over the meanings of the words “pilot” and “feasibility”. Pilot and Feasibility Studies provides a forum for discussion around this key aspect of the scientific process, and seeks to ensure that these studies are published, so as to complete the publication thread for clinical research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信